Janssen’s gene therapy for multiple myeloma patients, Carvykti (ciltacabtagene autoleucel), has been recommended for conditional EU-wide approval.
Carvykti is a CAR-T therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies. Approved in the US last month,...






